Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 5.19 HKD -8.3% Market Closed
Market Cap: 4.2B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ocumension Therapeutics
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Current Portion of Long-Term Debt
ÂĄ12.3m
CAGR 3-Years
86%
CAGR 5-Years
83%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Current Portion of Long-Term Debt
ÂĄ4.2B
CAGR 3-Years
625%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Current Portion of Long-Term Debt
ÂĄ27.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
12%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Current Portion of Long-Term Debt
ÂĄ36.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Current Portion of Long-Term Debt
ÂĄ68.7m
CAGR 3-Years
-58%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Current Portion of Long-Term Debt
ÂĄ179.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
4.2B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
4.66 HKD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
12.3m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Current Portion of Long-Term Debt amounts to 12.3m CNY.

What is Ocumension Therapeutics's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
83%

Over the last year, the Current Portion of Long-Term Debt growth was 0%. The average annual Current Portion of Long-Term Debt growth rates for Ocumension Therapeutics have been 86% over the past three years , 83% over the past five years .

Back to Top